A multicenter, open-label phase trial reported promise for an unresectable hepatocellular carcinoma regimen combining cadonilimab with lenvatinib and TACE (transarterial chemoembolization). The study evaluates how adding a PD-1 pathway agent to standard tyrosine kinase inhibition and locoregional treatment performs in patients who can’t undergo surgery or transplantation, a common HCC scenario. The results will likely influence how clinicians think about sequencing and combination design for in-liver disease control where local procedures remain feasible.